FOLH1 and prostate carcinoma: In most prostate cancer patients, [177Lu]Lu-PSMA uptake in skeletal metastases influences the bone-marrow absorbed dose, and considerably higher values with a median (range) of 100 (10–340) mGy/GBq have been reported for such cases [74].